A Phase 2 interventional study of Ranibizumab 0.3 mg and Ranibizumab 0.5 mg in Diabetic Macular Edema, sponsored by Novartis. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-02-24.
Sponsored by Novartis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.
Among the 91 studies testing ranibizumab in Macular Edema, this one is the 26th largest by enrollment, is the only one that started in 2005, is one of 19 in phase 2, and was the 2nd registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 28 · Phase 3 28 · Phase 4 26
First in 2004; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 151 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 50 across the 91 interventional studies. Of the 65 that completed or were terminated, 39 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 91 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
39 studies in Macular Edema by Novartis: none open now, none under way, none of them phase 3. Of 37 finished, 25 (68%) have results posted.
Among the 39 studies in Macular Edema by Novartis, this one is the 20th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2005, is one of 4 in phase 2, and was the 1st registered.
Novartis’s Macular Edema studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 91 studies testing ranibizumab in Macular Edema, from their registry updates:
Among Novartis’s 39 in Macular Edema:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluated the safety and efficacy of ranibizumab on retinal edema and visual acuity in patients with diabetic macular edema with center involvement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria applied to the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received monthly intravitreal injections with 0.3 mg ranibizumab (6 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 0.6 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
Drug: Ranibizumab 0.3 mg
Participants received monthly intravitreal injections with 0.5 mg ranibizumab (10 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 1.0 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
Drug: Ranibizumab 0.5 mg
Participants in the control group received 12 monthly sham intravitreal injections. The evaluation was performed using the same criteria for dose doubling as in active treatment groups. The injection was a mimicked by an empty syringe without a needle. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
Drug: Sham injection
6 mg/ml ranibizumab solution for intravitreal injection
10 mg/ml ranibizumab solution for intravitreal injection
Non-treatment control for sham intravitreal injection.
Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From Month 1 to Month 12
Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters as described in the Study Operations Manual.
Time frame: Baseline through the end of study (Month 12)
Mean Change From Baseline in Visual Acuity (Letters) of the Study Eye at Month 12
Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters as described in the Study Operations Manual.
Time frame: Baseline through the end of study (Month 12)
Mean Change From Baseline in Central Retinal Thickness (µm) of the Study Eye at Month 12
Optical Coherence Tomography (OCT) was assessed on both eyes at every study visit. These assessments were performed by trained personnel at the sites. OCT imaging was performed using the Zeiss Humphrey System Model 2000 (or later) with version A6.1 software running under Windows 95 or Windows 98. The analysis of the OCT images were performed by the Photographic Reading Center which provided a study manual and training materials. OCT operators, systems and software were certified prior to any evaluation of study patients.
Time frame: Baseline through the end of study (Month 12)
| Milestone | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|---|
| Started | 51 | 51 | 49 |
| Completed | 46 | 46 | 40 |
| Not completed | 5 | 5 | 9 |
| Withdrew: Adverse event | 1 | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 | 3 |
| Withdrew: Protocol violation | 0 | 1 | 2 |
| Withdrew: Withdrawal by subject | 2 | 2 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 |
| Withdrew: Death | 1 | 0 | 0 |
Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters as described in the Study Operations Manual.
| Letters | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|---|
| Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From Month 1 to Month 12 | 9.2 ± 5.60 | 6.4 ± 9.21 | -0.1 ± 9.77 |
Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters as described in the Study Operations Manual.
| Letters | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|---|
| Mean Change From Baseline in Visual Acuity (Letters) of the Study Eye at Month 12 | 11.8 ± 6.59 | 8.8 ± 10.99 | -1.4 ± 14.16 |
Optical Coherence Tomography (OCT) was assessed on both eyes at every study visit. These assessments were performed by trained personnel at the sites. OCT imaging was performed using the Zeiss Humphrey System Model 2000 (or later) with version A6.1 software running under Windows 95 or Windows 98. The analysis of the OCT images were performed by the Photographic Reading Center which provided a study manual and training materials. OCT operators, systems and software were certified prior to any evaluation of study patients.
| µm | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|---|
| Mean Change From Baseline in Central Retinal Thickness (µm) of the Study Eye at Month 12 | -200.7 ± 122.18 | -187.6 ± 147.82 | -48.4 ± 153.43 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.3 mg | — | 9/51 (17.6%) | 37/51 (72.5%) |
| Ranibizumab 0.5 mg | — | 9/51 (17.6%) | 43/51 (84.3%) |
| Sham Injection | — | 9/49 (18.4%) | 32/49 (65.3%) |
| Event | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|---|
| Angina pectorisCardiac disorders | 0/51 | 0/51 | 1/49 |
| Myocardial infarctionCardiac disorders | 0/51 | 1/51 | 1/49 |
| Retinal detachment (Study eye)Eye disorders | 0/51 | 0/51 | 1/49 |
| Pitting oedemaGeneral disorders | 0/51 | 0/51 | 1/49 |
| CellulitisInfections and infestations | 0/51 | 0/51 | 1/49 |
| Diabetic gangreneInfections and infestations | 0/51 | 0/51 | 1/49 |
| GastroenteritisInfections and infestations | 0/51 | 0/51 | 1/49 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 0/51 | 0/51 | 1/49 |
| Back painMusculoskeletal and connective tissue disorders | 0/51 | 0/51 | 1/49 |
| Renal failureRenal and urinary disorders | 0/51 | 0/51 | 1/49 |
| Event | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|---|
| Intraocular pressure increased (Study eye)Investigations | 6/51 | 15/51 | 1/49 |
| Conjunctival haemorrhage (Study eye)Eye disorders | 10/51 | 13/51 | 7/49 |
| Eye pain (Study eye)Eye disorders | 9/51 | 9/51 | 10/49 |
| Vitreous floaters (Study eye)Eye disorders | 1/51 | 8/51 | 0/49 |
| Visual acuity reduced (Study eye)Eye disorders | 1/51 | 6/51 | 5/49 |
| NasopharyngitisInfections and infestations | 5/51 | 5/51 | 1/49 |
| Conjunctivitis (Fellow eye)Eye disorders | 1/51 | 0/51 | 4/49 |
| Conjunctivitis (Study eye)Eye disorders | 1/51 | 1/51 | 4/49 |
| Ocular hyperaemia (Study eye)Eye disorders | 2/51 | 2/51 | 4/49 |
| Retinal exudates (Study eye)Eye disorders | 2/51 | 1/51 | 4/49 |
| Age Continuous(years) | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection | Total |
|---|---|---|---|---|
| Mean | 63.2 ± 10.44 | 62.8 ± 10.14 | 65.0 ± 9.26 | 63.6 ± 9.95 |
| Sex: Female, Male(Participants) | Ranibizumab 0.3 mg | Ranibizumab 0.5 mg | Sham Injection | Total |
|---|---|---|---|---|
| Female | 22 | 24 | 24 | 70 |
| Male | 29 | 27 | 25 | 81 |
The record gives a start of Oct 2005, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab